CIBC World Market’s Achillion Pharmaceuticals ACHN Stock Holding History

CIBC World Market’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-61,042	Closed	-$280K	–	1140
2017 Q2	$280K	Buy	+61,042	New	+$245K	﹤0.01%	991

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

CIBC World Market's ACHN Position: Q3 2017 in Review

CIBC World Market sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 61,042 shares — an estimated $280K sold.

CIBC World Market first reported a position in ACHN in Q2 2017 and held it in 1 quarter. The position peaked at $280K in Q2 2017. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

CIBC World Market reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
CIBC World Market sold 61,042 Achillion Pharmaceuticals shares in Q3 2017, an estimated $280K.
CIBC World Market first reported a position in Achillion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
CIBC World Market's Achillion Pharmaceuticals position peaked at $280K in Q2 2017.
125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on CIBC World Market's 13F filing for Q3 2017, filed 13 Nov 2017.